Japan Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden of cancer in Japan, how Takeda’s solutions help meet some of the country’s most significant unmet cancer needs, as well…
Global Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President of Childhood Cancer International (CCI) and Nicole Scobie, President of Zoé4life and CCI European Board Member, share CCI’s aims as the largest parent-led international organisation supporting…
Japan While the overall Japanese pharma market is expected to remain at a similar overall value up to 2023, the oncology segment is expected to grow by five percent and by 2026, oncology is expected to represent one-fifth of the entire market. Cancer is one of the top three leading causes…
Singapore Professor Ashok Venkitaraman introduces his work in Singapore, coordinating and catalysing research on the causes of cancer in Asia, and translating this research to clinical impact through improved detection, treatment and prevention. Professor Venkitaraman also outlines how the Singaporean research ecosystem compares to that of his former base in Cambridge,…
Europe Jasper Kunow, MSD’s managing director for Central Eastern Europe, outlines the threat that cancer still poses to Europe, the challenges of enacting the EU’s Beating Cancer Plan across the CEE region, and how policymakers and payers can help overcome them “In 2020, while we were all fighting against the…
China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.” We want…
Singapore Kenneth Tan has been President for Asia Pacific & Japan at cancer-focused medical device player Varian since February 2019. In a recent conversation with PharmaBoardroom, Tan shared how an early passion for healthcare has blossomed into an impressive global career in pharmaceuticals and MedTech, why a multidisciplinary, collaborative and patient-centric…
Europe The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating Cancer Plan to cancer patients in Europe, and its potential to boost the continent’s push to catch up with the US and China on biopharmaceutical innovation. Europe’s Beating Cancer Plan adds real momentum to the fight against cancer, promising…
Norway Photo: Sofia Linden / Oslo Cancer Cluster Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer…
Norway Norway, more well-known internationally as an innovation hub for oil & gas and marine biology, is attempting to reverse the trend of reducing numbers of clinical trials and cultivate a domestic healthcare research industry. Drawing on the country’s comprehensive health registries, universal healthcare system, links with its Nordic neighbours, and…
Norway Ole Alexander Opdalshei introduces the role of the Norwegian Cancer Society within Norwegian cancer research, care services and information dissemination; how medical research charities are able to direct funding towards areas of cancer research missed by the private and public sectors; the burden of cancer within Norway; and the introduction…
Norway Ketil Widerberg of the Oslo Cancer Cluster highlights how Norway’s excellence in electronic health records can help the country stake out a position as a significant cancer research destination. Widerberg also highlights the Cluster’s work to bridge seemingly disparate actors right across the oncology value chain, its collaboration with the…
See our Cookie Privacy Policy Here